Developments Oncogene publishes remission for testicular cancer patient treated with MiNK’s iNKT cell therapy MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer... July 11, 2025